Drug intelligence / Profile preview

NKR-2 cells + FOLFOX

Development stage: Unknown
Lead developer: Celyad Oncology
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Intravenous

Overview

NKR-2 cells + FOLFOX is an investigational combination therapy under clinical development for cancer, primarily metastatic colorectal cancer. It combines **NKR-2 cells**, which are autologous T cells genetically engineered to express the NKG2D chimeric antigen receptor (CAR), with the standard chemotherapy regimen **FOLFOX**—a combination of folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin. NKR-2 cells recognize a broad range of tumor-expressed ligands (MIC-A, MIC-B, ULBP1-6), enabling multi-targeted tumor cell killing, immune modulation (reducing regulatory T cells and myeloid-derived suppressor cells, recruiting macrophages), and anti-angiogenic activity. FOLFOX works by directly inhibiting DNA synthesis and cell division in rapidly dividing cancer cells. The combination aims to enhance anti-tumor efficacy by integrating the direct cytotoxic effects of chemotherapy with the immune-mediated and multi-pronged mechanisms of CAR T NKR-2 cells.

Other names: NKR-2 T-cells + FOLFOXNKR-2 + FOLFOX

Targets

RAET1E (UL16-binding protein 4)TS (Thymidylate synthase)MICA (Major histocompatibility complex class I-related protein A)ULBP1 (UL16-binding protein 1)ULBP2 (UL16-binding protein 2)DNAULBP6 (UL16-binding protein 6)ULBP5 (UL16-binding protein 5)ULBP3 (UL16 binding protein 3)MICB (Major histocompatibility complex class i-related protein B)

Beyond the preview

Go deeper on NKR-2 cells + FOLFOX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NKR-2 cells + FOLFOX.

Explore the full profile